Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Major Domestic Firms Feel Cool to Pfizer's Move
July 29, 2002
- InCROM Establishes EuCROM to Handle CRO Business in Europe
July 29, 2002
- CORPORATE ROUNDUP NEWS IN BRIEF
July 29, 2002
- MEDICAL DEVICE NEWS IN BRIEF
July 29, 2002
- 4.3% of ex-Koseisho Officials Were Aware of Risk of Hepatitis Due to Fibrinogen
July 29, 2002
- WORLD NEWS IN BRIEF
July 29, 2002
- Health Minister Concerned about Delay in Domestic R&D
July 29, 2002
- Nippon Kayaku Not to Spin Off Non-Pharma Business: Mr Nakamura
July 29, 2002
- NEW PRODUCTS
July 29, 2002
- Tanabe Aims at World-class Performance for Each Division: President Hayama
July 29, 2002
- FY2003 Budget Formation Schedule Confirmed
July 29, 2002
- US Consumers Appreciate Online Healthcare Information: PhRMA Seminar
July 29, 2002
- Kyowa Hakko Pharma Business to Focus on Cancer, Allergy
July 22, 2002
- 11 of 15 Major Firms Introduce Researchers Rewarding Programs: Survey
July 22, 2002
- Nippon Kayaku Licensed Paclitaxel DDS from NanoCarrier
July 22, 2002
- Korosho Panel Recommends GLs for Infertility Therapy
July 22, 2002
- Fujisawa Licenses Cefzon to Xian-Janssen in China
July 22, 2002
- GL to Include MNZ in Secondary H. pylori Eradication Therapy
July 22, 2002
- Wholesaler-Maker Relationship Undergoing Drastic Changes: Mr Akiyama of Suzuken
July 22, 2002
- Olympus Codevelops New DNA Microarray System with PamGene
July 22, 2002
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…